Clinical Report: Orforglipron for Sustaining Weight Loss: Results from the ATTAIN-MAINTAIN Study
Overview
The ATTAIN-MAINTAIN study evaluated the efficacy and safety of orforglipron in maintaining weight loss after transitioning from injectable therapies. Results indicate that orforglipron effectively supports weight maintenance in individuals with obesity, demonstrating a favorable safety profile.
Background
Obesity is a chronic disease that often requires long-term management strategies to prevent weight regain after initial loss. Injectable obesity management medications (OMMs) have shown efficacy, but patient adherence remains a challenge. Orforglipron, a novel oral GLP-1 receptor agonist, presents a potential solution by addressing barriers associated with injectable therapies.
Orforglipron demonstrated significant weight maintenance after transitioning from injectable therapies.
Completion rates were high, with 85.9% in cohort 1 and 84.2% in cohort 2.
The study included 376 participants across 29 sites in the USA.
Orforglipron's safety profile was comparable to that of existing injectable OMMs.
Participants had a mean age of 48.5 years, predominantly female (62.9%) and white (73.8%).
Clinical Implications
The findings suggest that orforglipron may enhance patient adherence to weight management regimens by providing a non-injectable option. Clinicians should consider this oral therapy as part of a comprehensive obesity management plan, particularly for patients who struggle with injectable treatments.
Conclusion
Orforglipron represents a promising advancement in obesity management, potentially improving long-term weight maintenance outcomes for patients transitioning from injectable therapies.
by Louis J. Aronne, Deborah B. Horn, Carel W. le Roux, Ariana M. Chao, Wayne Ho, Bruno Halpern, Ryan Griffin, Cathy Xie, Elisa Gomez Valderas, Clare J. Lee, Anderson Ribeiro, David M. Hyman, Leonard Glass, Neena Xavier
